CELC Latest Press Releases

-- September 1, 2026 --

Celcuity To Participate in Upcoming Investor Conferences Globe Newswire 8:30 AM

-- August 26, 2026 --

Celcuity Submits sNDA to FDA for REVTORPYK (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer Globe Newswire 8:30 AM

-- August 13, 2026 --

Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:06 PM

-- August 6, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC PRNewswire 11:02 PM

-- August 4, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC Globe Newswire 5:45 PM

Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm Globe Newswire 5:43 PM

-- August 3, 2026 --

CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations Business Wire 8:19 PM

-- August 2, 2026 --

CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law Business Wire 5:27 PM

-- July 31, 2026 --

CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm PRNewswire 11:22 AM

-- July 30, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsnOn Behalf of Investors of Celcuity Inc. - CELC PRNewswire 10:01 AM

Newly FDA-Approved REVTORPYK (gedatolisib) Included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer Globe Newswire 8:30 AM

-- July 29, 2026 --

NASDAQ: CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm Globe Newswire 10:55 AM

-- July 28, 2026 --

NASDAQ: CELC Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm Business Wire 7:50 PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC Globe Newswire 5:31 PM

-- July 21, 2026 --

CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm Globe Newswire 4:58 PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC Globe Newswire 1:26 PM

-- July 20, 2026 --

CELC INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud Globe Newswire 8:00 PM

-- July 16, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC PRNewswire 7:52 PM

-- July 14, 2026 --

Celcuity Announces FDA Approval of REVTORPYK (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer Globe Newswire 4:53 PM

-- June 3, 2026 --

Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032 Globe Newswire 10:13 PM

Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032 Globe Newswire 7:19 AM

-- June 2, 2026 --

Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer Globe Newswire 8:25 AM

-- June 1, 2026 --

Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026 Globe Newswire 8:30 AM

-- May 28, 2026 --

Celcuity To Participate in Upcoming Investor Conferences Globe Newswire 8:30 AM

-- May 14, 2026 --

Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:01 PM

Celcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients Globe Newswire 7:30 AM

-- May 7, 2026 --

Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call Globe Newswire 8:00 AM

-- May 1, 2026 --

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort Globe Newswire 5:03 PM